1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTissue Chip for Drug Screening Program is sponsored by National Center for Advancing Translational Sciences (NCATS) / National Institutes of Health (NIH). This program aims to develop bioengineered devices, also called organs-on-chips, that mimic the structure and function of human organ systems.
Get alerted about grants like this
Save a search for “National Center for Advancing Translational Sciences (NCATS) / National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Tissue Chip for Drug Screening | National Center for Advancing Translational Sciences U.S. Department of Health & Human Services National Institutes of Health Tissue Chip for Drug Screening The Tissue Chip for Drug Screening program aims to develop bioengineered devices to improve the process of predicting whether drugs will be safe or toxic in humans. Passley Hargrove-Grimes, Ph. D.
Dmitriy V. Krepkiy, Ph. D.
View the 3-D Tissue Models fact sheet (PDF - 222KB) Many promising medications have failed to be safe and effective in human clinical trials despite promising preclinical studies. We are addressing this problem through the Tissue Chip for Drug Screening program. We coordinate with other NIH institutes and centers and the U.S. Food and Drug Administration (FDA) .
Tissue chips are built from human cells. Also called organs-on-chips, they mimic the structure and function of our heart, kidneys, lungs and other organ systems. Scientists are developing and using tissue chips to test the potential effects of drugs on those tissues in a faster and more effective way than current methods.
Learn more about these projects . With flexible funding from the Cures Acceleration Network , we focus on developing high-need cures and reducing major barriers between research discovery and clinical trials. Our Tissue Chip for Drug Screening program aims to speed the translation of basic discoveries into the clinic.
By creating an integrated human body-on-a-chip , researchers will be able to test the possible effects of a drug or other substance across the entire body before testing in people. Because they use human cells, tissue chips are also useful research tools to study human diseases and conditions when animal models do not mirror the pathology or are unavailable.
They support NIH’s position that non-animal model approaches can reduce the need for animals in research but will require further improvement to completely replace them. Tissue Chips in Space 2.
0 Will Reveal Age-Related Disease Mechanisms and Possible Therapies February 17, 2026 - NCATS News Tissue Chip for Drug Screening NIH selected researchers to design microphysiological technologies that mimic human organ systems for age-related disease experiments at the International Space Station National Laboratory.
Faculty Member Joins Major NIH-Funded Center to Improve Chemical Safety Assessment Faculty Member Joins Major NIH-Funded Center to Improve Chemical Safety Assessment April 16, 2026 - Grantee/Partner News Our Impact on Research Operations Tissue Chip for Drug Screening Wyss Institute Technologies Enable Breakthrough in Astronaut Health Research Aboard NASA’s Artemis II Mission Wyss Institute Technologies Enable Breakthrough in Astronaut Health Research Aboard NASA’s Artemis II Mission April 9, 2026 - Grantee/Partner News Tissue Chip for Drug Screening NIH Invests $150 Million in Human-Based Research to Reduce Use of Animal Models NIH Invests $150 Million in Human-Based Research to Reduce Use of Animal Models March 18, 2026 - Grantee/Partner News Clinical and Translational Science Awards (CTSA) Program Tissue Chip for Drug Screening See More Tissue Chip News Watch the Tissue Chip for Drug Screening video (video length: 3:49) to learn more about the program.
Stem Cell Translation Laboratory Our experts develop methods and standards to use stem cell technology (using cells derived from skin or blood) to advance treatment approaches. Our scientists are creating and using 3-D printing techniques to make tissue models that closely resemble the complex structure and organization of our cells.
Matrix Combination Screening Our experts use matrix combination screening technology to quickly identify promising drug combinations with the most potential to help patients. Last updated on December 26, 2025
According to the current listing, eligibility includes: Researchers and institutions involved in developing microphysiological systems and tissue chip technology. Universities are eligible. Confirm the full requirements in the official notice before applying.
The current listing shows NIH plans to commit up to $70 million over five years for the program (initial funding in 2012). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Tissue Chip for Drug Screening Program is funded by National Center for Advancing Translational Sciences (NCATS) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Translational Centers for Microphysiological Systems (TraCe MPS) is sponsored by National Center for Advancing Translational Sciences (NCATS) / National Institutes of Health (NIH). NCATS has established new centers to strengthen the use of organ-on-a-chip, or tissue chip, technology to develop drugs and potentially reduce the need for animals in research.
Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS) / National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, and Fast-Track grant applications.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read article